Qiagen (QGEN) News Today

Qiagen N.V. (NYSE: QGEN) shares have been supported by stronger-than-expected preliminary third-quarter results and the announced acquisition by EQT, although the deal’s fixed cash consideration and shareholder investigations may limit further upside.

• Positive Sentiment: Qiagen updated third-quarter 2026 guidance to adjusted EPS of $0.65 and revenue of $548 million, above consensus estimates of $0.62 and $534.1 million, respectively. The figures are consistent with the company’s preliminary results and signal better-than-expected operating performance.
• Positive Sentiment: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share. The takeover provides a defined valuation and has been unanimously accepted, with the transaction nearing completion. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Robert W. Baird raised its price target to $52 from $50 and upgraded the stock to “outperform,” citing potential value near the takeover consideration. Robert W. Baird Qiagen rating
• Neutral Sentiment: Unusually heavy call-option activity suggests increased short-term trading interest, with call purchases roughly doubling typical volume, but it does not establish a fundamental change in valuation.
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating while lowering its price target to $52 from $55, leaving limited projected upside relative to the current trading level. JPMorgan Qiagen rating
• Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen obtained a fair price for shareholders. Such reviews could create deal uncertainty, although they do not currently indicate that the transaction will be blocked. Brodsky & Smith shareholder investigation